Specification
Description
Cadrofloxacin, also known as Caderofloxacin and CS-940, is a novel fluoroquinolone antibacterial. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.
Synonyms
CS-940; CS 940; CS940; Cadrofloxacin; Caderofloxacin; Cadrofloxacin hydrochloride; Cadrofloxacin HCl
IUPAC Name
(S)-1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Canonical SMILES
O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@H](C)NCC4)=C3OC(F)F)C1=O)O
InChI
InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1
InChI Key
QBDBUKJBJJWZMG-VIFPVBQESA-N
Boiling Point
602.4ºC at 760mmHg
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Alternative CAS
128427-55-4 (HCl); 153808-85-6 (free base)
Biological Target
Cadrofloxacin (Caderofloxacin; CS-940), an active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 55.47; H, 4.90; F, 13.85; N, 10.21; O, 15.56
HS Tariff Code
2934.99.9001
In Vitro Activity
The in vitro activities of CS-940, a new fluoroquinolone, were compared with those of a group of other drugs. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml.
Reference: Antimicrob Agents Chemother. 1997 Nov;41(11):2582-5. https://pubmed.ncbi.nlm.nih.gov/9371375/
In Vivo Activity
The in vivo activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone, were compared with those of ciprofloxacin, tosufloxacin, sparfloxacin, and levofloxacin. CS-940 showed potent bactericidal activity against S. aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. In oral treatment of mouse systemic infections caused by S. aureus, Streptococcus pneumoniae, Streptococcus pyogenes, E. coli, K. pneumoniae, Serratia marcescens, and P. aeruginosa, CS-940 was more effective than ciprofloxacin, sparfloxacin, and levofloxacin against all strains tested. Against experimental pneumonia with K. pneumoniae in mice, CS-940 was the most effective of all the quinolones tested. These results suggest that CS-940 may be effective in the therapy of various bacterial infections.
Reference: Antimicrob Agents Chemother. 1996 May;40(5):1201-7. https://pubmed.ncbi.nlm.nih.gov/8723467/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).